Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, fluid management, electrophysiology and cardiac rhythm management, and hemodynamic monitoring to treat various heart conditions. The company also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, swab and collection systems, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, it provides pulmonary products that consist of laser-cut tracheobronchial stents, advanced over-the-wire and direct visualization delivery systems, and dilation balloons; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. The company sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
IPO Year:
Exchange: NASDAQ
Website: merit.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/28/2024 | $96.00 | Outperform | Robert W. Baird |
| 4/11/2024 | $88.00 | Buy | CL King |
| 2/7/2024 | $87.00 | Neutral | BofA Securities |
| 12/21/2023 | $100.00 | Hold → Buy | Canaccord Genuity |
| 12/20/2022 | $73.00 → $72.00 | Buy → Hold | Canaccord Genuity |
| 2/25/2022 | $73.00 → $72.00 | Outperform | Raymond James |
| 2/25/2022 | $83.00 → $73.00 | Buy | Needham |
| 10/29/2021 | $68.00 → $74.00 | Equal-Weight | Wells Fargo |
| 7/30/2021 | $69.00 → $73.00 | Outperform | Raymond James |
| 7/30/2021 | $65.00 → $68.00 | Equal-Weight | Wells Fargo |
For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13D/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SOUTH JORDAN, Utah, May 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced that its shareholders elected Silvia M. Perez, President of the Commercial Branding and Transportation Division at 3M Company, as a director in Merit's Annual Meeting of Shareholders held on May 15, 2024. Merit's shareholders also re-elected Fred P. Lampropoulos and Stephen C. Evans as directors. Ms. Perez and Messrs. Lampropoulos and Evans were elected to serve three-year terms. "We are pleased to welcome Silvia Perez as our newest director," said Mr. Lampropoulos, Merit's Chairman and Chief Executive Officer. "Her expertise and proven
Joe Wright Appointed President Expands Deep Bench of Leadership Team Talent; Supports "Continued Growth Initiatives" Program SOUTH JORDAN, Utah, May 15, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced the appointment of Joe Wright as President, effective immediately. As President, Mr. Wright will be responsible for the oversight of Merit's global commercial, marketing, and manufacturing operations. Mr. Wright has been an instrumental part of the Merit team over the past 19 years. He most recently served as Chief Commercial Officer, where he led the development and expansion of Merit's global commercial activit
SOUTH JORDAN, Utah, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, today outlined the ongoing succession planning process for its Chief Executive Officer (CEO). Pursuant to an Amended and Restated Employment Agreement, effective June 8, 2023, Merit founder, CEO, and President, Fred Lampropoulos, will continue to serve as Merit's CEO and President through December 31, 2025. To carry out its responsibility for CEO succession, the Merit Board of Directors appointed a special steering committee of independent directors led by Ann Millner, Ed.D., Lead Independent Director. The committee is deve
SOUTH JORDAN, Utah, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the appointment of Merit's long-time executive, Joe Wright, as Merit's Chief Commercial Officer. In this role, Joe will be responsible for spearheading the company's overall commercial strategy. Joe's career at Merit began over seventeen years ago. Highly regarded for his deep international experience, Joe recently was the President of International leading business units across APAC and the Americas. For the past year, he also had commercial responsibility for EMEA. His previous positions include serving as P
SOUTH JORDAN, Utah, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader in healthcare technology, today reported that it has completed the acquisition of Cook Medical's lead management portfolio. The purchase consideration consisted of a cash payment of approximately $210 million and the assumption of certain liabilities. Merit funded the acquisition payment through a combination of cash on hand and borrowings under its long-term credit facility. "We are pleased to announce the completion of this important acquisition," said Fred P. Lampropoulos, Merit's Chairman and Chief Executive Officer. "We are excited to welcome the talented team from Cook Me
Third Quarter 2024 Highlights† Reported revenue of $339.8 million, up 7.8%Constant currency revenue* and constant currency revenue, organic* up 7.9% and up 5.7%, respectivelyGAAP operating margin of 11.0%, compared to 11.1% in prior year periodNon-GAAP operating margin* of 19.2%, compared to 17.4% in prior year periodGAAP EPS $0.48, up 8.0%, and non-GAAP EPS* $0.86, up 21.1%Generated free cash flow* $120 million over the first nine months of 2024, up 116% year-over-yearCompleted the acquisition of certain assets from EndoGastric Solutions, Inc., which included the EsophyX® Z+, a device intended for the treatment of chronic gastroesophageal reflux diseaseAnnounced positive 6-month findings
SOUTH JORDAN, Utah, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2024, after the close of the stock market on Wednesday, October 30, 2024. Merit will hold its investor conference call on the same day (Wednesday, October 30, 2024) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide dec
Asset acquisition of Cook Medical's end-to-end lead management product portfolio strengthens Merit's existing electrophysiology and CRM business Asset acquisition projected to add approximately $40 million of revenue, on an annualized basis beginning in fiscal year 2025, with a solid growth profile serving an underpenetrated global lead management market Merit reaffirms full-year 2024 financial guidance previously issued on August 1, 2024, and updates full-year 2024 financial guidance to include the projected impact from this acquisition post-close SOUTH JORDAN, Utah, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader in healthcare technolo
SOUTH JORDAN, Utah, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced positive 6-month findings from the randomized arteriovenous (AV) fistula arm of its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial. The data were shown at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) during a FIRST@CIRSE presentation. WRAPSODY is a cell-impermeable endoprosthesis which is intended to extend long-term vessel patency in dialysis patients. Many patients undergoing dialysis rely on a vascular access site created in the arm called an AV fistula. The maintenance of adequate blood
SOUTH JORDAN, Utah, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that clinicians will present updates on two of its pivotal studies during scientific sessions held on September 14 at CIRSE in Lisbon, Portugal. Data will include 6-month clinical outcomes from the WAVE study, presented during the FIRST@CIRSE Clinical Trial session held between 11:30 and 12:30. An overview of the MOTION study design and methodology will be presented during the News on Stage session, "Meet the Brains Behind These Landmark Trials," held between 13:00 and 14:00. In addition to presenting at sci
Second Quarter 2024 Highlights† Reported revenue of $338.0 million, up 5.6%Constant currency revenue* up 6.6%Constant currency revenue, organic,* up 5.0%GAAP operating margin of 13.6%, compared to 9.0% in prior year periodNon-GAAP operating margin* of 20.1%, compared to 19.1% in prior year periodGAAP EPS $0.61, up 75.7%Non-GAAP EPS* $0.92, up 16.8% † Comparisons noted in the bullet points are calculated for the current quarter compared with the same prior year period unless otherwise specified. * The constant currency revenue; constant currency revenue, organic; non-GAAP gross profit and margin; non-GAAP operating income and margin; non-GAAP net income; non-GAAP EPS; and
SOUTH JORDAN, Utah, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced plans to release findings from its WAVE study. A pivotal, international, multicenter trial, the WAVE study examines the safety and efficacy of Merit's WRAPSODY Cell-Impermeable Endoprosthesis for treatment of stenosis in the venous outflow circuit. The WAVE study enrolled 245 patients with stenosis in their arteriovenous fistula (AVF) and 113 patients with evidence of stenosis in their arteriovenous graft (AVG). Patients with an AVF were randomized 1:1 to treatment with WRAPSODY or standard of care with percutaneous transluminal angiopl
Asset acquisition expands Merit's endoscopy portfolio with a minimally invasive solution for patients suffering from chronic gastroesophageal reflux disease (GERD). Asset acquisition projected to add approximately $30 million of revenue, on an annualized basis, in key gastrointestinal endoscopy market that leverages existing commercial footprint. Merit reaffirms full-year 2024 financial guidance on standalone basis and updates full-year 2024 financial guidance to include projected partial-year impact from this acquisition. SOUTH JORDAN, Utah, July 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announ
SOUTH JORDAN, Utah, June 18, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2024, after the close of the stock market on Thursday, August 1, 2024. Merit will hold its investor conference call on the same day (Thursday, August 1, 2024) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed
Robert W. Baird initiated coverage of Merit Medical with a rating of Outperform and set a new price target of $96.00
CL King initiated coverage of Merit Medical with a rating of Buy and set a new price target of $88.00
BofA Securities initiated coverage of Merit Medical with a rating of Neutral and set a new price target of $87.00
Canaccord Genuity upgraded Merit Medical from Hold to Buy and set a new price target of $100.00
Canaccord Genuity downgraded Merit Medical from Buy to Hold and set a new price target of $72.00 from $73.00 previously
Raymond James reiterated coverage of Merit Medical Systems with a rating of Outperform and set a new price target of $72.00 from $73.00 previously
Needham reiterated coverage of Merit Medical Systems with a rating of Buy and set a new price target of $73.00 from $83.00 previously
Wells Fargo reiterated coverage of Merit Medical Systems with a rating of Equal-Weight and set a new price target of $74.00 from $68.00 previously
Raymond James reiterated coverage of Merit Medical Systems with a rating of Outperform and set a new price target of $73.00 from $69.00 previously
Wells Fargo reiterated coverage of Merit Medical Systems with a rating of Equal-Weight and set a new price target of $68.00 from $65.00 previously
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
SOUTH JORDAN, Utah, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader in healthcare technology, today reported that it has completed the acquisition of Cook Medical's lead management portfolio. The purchase consideration consisted of a cash payment of approximately $210 million and the assumption of certain liabilities. Merit funded the acquisition payment through a combination of cash on hand and borrowings under its long-term credit facility. "We are pleased to announce the completion of this important acquisition," said Fred P. Lampropoulos, Merit's Chairman and Chief Executive Officer. "We are excited to welcome the talented team from Cook Me
Third Quarter 2024 Highlights† Reported revenue of $339.8 million, up 7.8%Constant currency revenue* and constant currency revenue, organic* up 7.9% and up 5.7%, respectivelyGAAP operating margin of 11.0%, compared to 11.1% in prior year periodNon-GAAP operating margin* of 19.2%, compared to 17.4% in prior year periodGAAP EPS $0.48, up 8.0%, and non-GAAP EPS* $0.86, up 21.1%Generated free cash flow* $120 million over the first nine months of 2024, up 116% year-over-yearCompleted the acquisition of certain assets from EndoGastric Solutions, Inc., which included the EsophyX® Z+, a device intended for the treatment of chronic gastroesophageal reflux diseaseAnnounced positive 6-month findings
SOUTH JORDAN, Utah, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2024, after the close of the stock market on Wednesday, October 30, 2024. Merit will hold its investor conference call on the same day (Wednesday, October 30, 2024) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide dec
Second Quarter 2024 Highlights† Reported revenue of $338.0 million, up 5.6%Constant currency revenue* up 6.6%Constant currency revenue, organic,* up 5.0%GAAP operating margin of 13.6%, compared to 9.0% in prior year periodNon-GAAP operating margin* of 20.1%, compared to 19.1% in prior year periodGAAP EPS $0.61, up 75.7%Non-GAAP EPS* $0.92, up 16.8% † Comparisons noted in the bullet points are calculated for the current quarter compared with the same prior year period unless otherwise specified. * The constant currency revenue; constant currency revenue, organic; non-GAAP gross profit and margin; non-GAAP operating income and margin; non-GAAP net income; non-GAAP EPS; and
Asset acquisition expands Merit's endoscopy portfolio with a minimally invasive solution for patients suffering from chronic gastroesophageal reflux disease (GERD). Asset acquisition projected to add approximately $30 million of revenue, on an annualized basis, in key gastrointestinal endoscopy market that leverages existing commercial footprint. Merit reaffirms full-year 2024 financial guidance on standalone basis and updates full-year 2024 financial guidance to include projected partial-year impact from this acquisition. SOUTH JORDAN, Utah, July 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announ
SOUTH JORDAN, Utah, June 18, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2024, after the close of the stock market on Thursday, August 1, 2024. Merit will hold its investor conference call on the same day (Thursday, August 1, 2024) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed
Q1 2024 reported revenue of $323.5 million, up 8.7% compared to Q1 2023Q1 2024 constant currency revenue* up 9.3% compared to Q1 2023Q1 2024 constant currency revenue, organic* up 7.0% compared to Q1 2023Q1 2024 GAAP operating margin of 11.1%, compared to 8.9% in Q1 2023Q1 2024 non-GAAP operating margin* of 17.3%, compared to 16.1% in Q1 2023Q1 2024 GAAP EPS $0.48, up 35.5%, compared to $0.36 in Q1 2023Q1 2024 non-GAAP EPS* $0.77, up 18.7%, compared to $0.64 in Q1 2023 * Constant currency revenue; constant currency revenue, organic; non-GAAP gross profit and margin; non-GAAP operating income and margin; non-GAAP net income; non-GAAP EPS; and free cash flow are non-GAAP financial measures. A
SOUTH JORDAN, Utah, March 18, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2024, after the close of the stock market on Tuesday, April 30, 2024. Merit will hold its investor conference call on the same day (Tuesday, April 30, 2024) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed using this
Q4 2023 reported revenue of $324.5 million, up 10.6% year-over-yearQ4 2023 constant currency revenue* up 10.3% year-over-yearQ4 2023 constant currency revenue, organic* up 8.3% year-over-yearQ4 2023 GAAP operating margin of 10.4%, compared to 10.4% in Q4 2022Q4 2023 non-GAAP operating margin* of 18.2%, compared to 17.8% in Q4 2022Q4 2023 GAAP EPS $0.47, compared to $0.58 in Q4 2022Q4 2023 non-GAAP EPS* $0.81, compared to $0.79 in Q4 2022Issues fiscal year 2024 financial guidance * Constant currency revenue; constant currency revenue, organic; non-GAAP EPS; non-GAAP net income; non-GAAP operating income and margin; non-GAAP gross profit and margin; and free cash flow are non-GAAP financial
SOUTH JORDAN, Utah, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, today introduced its Continued Growth Initiatives Program and related financial targets for the three-year period ending December 31, 2026. Merit's new multi-year financial targets are: Total revenue increase at a compound annual growth rate (CAGR) of 5% to 7% on an organic, constant currency, basis* for the three-year period ending December 31, 2026.Non-GAAP operating margin* of 20.0% to 22.0% for the year ending December 31, 2026.Cumulative free cash flow* generation of at least $400 million for the three-year
9 analysts have expressed a variety of opinions on Merit Medical Systems (NASDAQ:MMSI) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 5 0 0 0 Last 30D 0 1 0 0 0 1M Ago 2 2 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 2 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $99.78, with a high estimate of $125.00 and a low estimate of $85.00. Witnessing
Barrington Research analyst Michael Petusky maintains Merit Medical Systems (NASDAQ:MMSI) with a Outperform and maintains $100 price target.
Barrington Research analyst Michael Petusky maintains Merit Medical Systems (NASDAQ:MMSI) with a Outperform and maintains $100 price target.
Canaccord Genuity analyst Jon Young maintains Merit Medical Systems (NASDAQ:MMSI) with a Buy and raises the price target from $102 to $125.
Needham analyst Mike Matson maintains Merit Medical Systems (NASDAQ:MMSI) with a Buy and raises the price target from $85 to $93.
Asset acquisition expands Merit's endoscopy portfolio with a minimally invasive solution for patients suffering from chronic gastroesophageal reflux disease (GERD).Asset acquisition projected to add approximately $30 million of revenue, on an annualized basis, in key gastrointestinal endoscopy market that leverages existing commercial footprint. Merit reaffirms full-year 2024 financial guidance on standalone basis and updates full-year 2024 financial guidance to include projected partial-year impact from this acquisition. SOUTH JORDAN, Utah, July 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced it has executed a
Merit Medical Systems (NASDAQ:MMSI) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 2 0 0 0 3M Ago 2 1 0 0 0 Analysts have set 12-month price targets for Merit Medical Systems, revealing an average target of $94.25, a high estimate of $102.00, and a low estimate of $85.00. A decline of 4.02% from the prior a
Baird analyst David Rescott initiates coverage on Merit Medical Systems (NASDAQ:MMSI) with a Outperform rating and announces Price Target of $96.
Merit Medical Systems's (NYSE:MMSI) short percent of float has risen 7.84% since its last report. The company recently reported that it has 2.51 million shares sold short, which is 6.33% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.39 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short i
8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
10-Q - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
S-8 - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
10-Q - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
11-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
SD - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)